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OBJECTIVES The Transplantation of Progenitor Cells And Regeneration Enhancement in Acute Myo-
cardial Infarction (TOPCARE-AMI) trial investigates both safety, feasibility, and potential
effects on parameters of myocardial function of intracoronary infusion of either circulating
progenitor cells (CPC) or bone marrow-derived progenitor cells (BMC) in patients with
acute myocardial infarction (AMI).
BACKGROUND In animal experiments, therapy with adult progenitor cells was shown to improve vascular-
ization, left ventricular (LV) remodeling, and contractility after AMI.
METHODS A total of 59 patients with AMI were randomly assigned to receive either CPC (n  30) or
BMC (n  29) into the infarct artery at 4.9  1.5 days after AMI.
RESULTS Intracoronary progenitor cell application did not incur any measurable ischemic myocardial
damage, but one patient experienced distal embolization before cell therapy. During hospital
follow-up, one patient in each cell group developed myocardial infarction; one of these
patients died of cardiogenic shock. No further cardiovascular events, including ventricular
arrhythmias or syncope, occurred during one-year follow-up. By quantitative LV angiography
at four months, LV ejection fraction (EF) significantly increased (50  10% to 58  10%;
p  0.001), and end-systolic volumes significantly decreased (54  19 ml to 44  20 ml; p
 0.001), without differences between the two cell groups. Contrast-enhanced magnetic
resonance imaging after one year revealed an increased EF (p  0.001), reduced infarct size
(p  0.001), and absence of reactive hypertrophy, suggesting functional regeneration of the
infarcted ventricles.
CONCLUSIONS Intracoronary infusion of progenitor cells (either BMC or CPC) is safe and feasible in
patients after AMI successfully revascularized by stent implantation. Both the excellent safety
profile and the observed favorable effects on LV remodeling, provide the rationale for larger
randomized double-blind trials. (J Am Coll Cardiol 2004;44:1690–9) © 2004 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.014American College of Cardiology Foundation
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post-infarction heart failure remains a major cause of
orbidity and mortality (1). Although prompt reperfusion
f the occluded artery has significantly reduced early mor-
ality rates (2), contemporary reperfusion strategies using
ercutaneous coronary intervention were shown to be asso-
iated with modest improvements in global left ventricular
LV) function as evidenced by a 2% to 4% increase in
jection fraction (EF) six months after an acute myocardial
nfarction (AMI) (3,4). The major goal to improve post-
nfarction LV function further would be the stimulation of
eovascularization and the enhancement of regeneration of
ardiac myocytes within the infarct area.
From the Departments of *Cardiology, †Radiology, and ‡Hematology, Johann
olfgang Goethe-University Frankfurt, Frankfurt, Germany. Supported by the DFG
Di 600/4-1; FOR 501-1 and WA 146/2-1). Drs. Schächinger and Assmus
ontributed equally to this work.q
Manuscript received June 8, 2004; revised manuscript received June 24, 2004,
ccepted August 2, 2004.Recent experimental studies suggested that bone marrow-
erived progenitor cells (BMC) or circulating progenitor
ells (CPC) might contribute to the regeneration of in-
arcted myocardium and enhance neovascularization of
schemic myocardium (5–8). Moreover, either intravenous
nfusion or intramyocardial injection of adult progenitor
ells resulted in sustained improvement of cardiac function
oth after experimentally induced myocardial infarction (MI)
5–9) and in initial pilot studies in patients with acute and
hronic ischemic heart disease (10–14). We initiated the
ransplantation of Progenitor Cells And Regeneration En-
ancement in Acute Myocardial Infarction (TOPCARE-
MI) trial as a comprehensive pilot study to document the
linical safety and feasibility of intracoronary progenitor cell
nfusion and to quantitate parameters of LV function and
emodeling after MI in order to estimate potential effects of
rogenitor cell therapy necessary to adequately design subse-
uent double-blind controlled trials. The present report de-
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October 19, 2004:1690–9 Intracoronary Progenitor Cells After AMIcribes the final results of the TOPCARE-AMI trial including
ne-year follow-up of all patients.
ETHODS
atients. Between October 2001 and March 2003, a total
f 59 patients with acute ST-segment elevation MI were
ecruited into the study at a single center. Because of the
xperimental nature of the treatment, the study protocol
alled for an interim analysis of the outcome data after the
rst 20 patients completed their four months’ invasive
ollow-up. The data of these first 20 patients have been
ublished previously (14). In addition, data on four-month
agnetic resonance imaging (MRI) follow-up have been
eported (15) in 26 of the patients.
Patients between 18 and 75 years of age were eligible for
nclusion into the study if they had a first ST-segment
Abbreviations and Acronyms
AMI  acute myocardial infarction
BMC  bone marrow-derived progenitor
cells
CPC  circulating progenitor cells
EF  ejection fraction
LAD  left anterior descending
LV  left ventricular
MI  myocardial infarction
MRI  magnetic resonance imaging
TOPCARE-AMI  Transplantation of Progenitor Cells
And Regeneration Enhancement in
Acute Myocardial Infarction trialigure 1. Trial design (see text for details). AMI  acute myocardial infarcti
rogenitor cells; LV  left ventricular; MI  myocardial infarction; MRI  mlevation AMI, which was treated by coronary stenting
sing bare metal stents with glycoprotein IIb/IIIa blockade
tirofiban, eptifibatide, or abciximab) in the acute phase of
I. Exclusion criteria were the presence of cardiogenic
hock (defined as systolic blood pressure 80 mm Hg
equiring intravenous pressors or intra-aortic balloon coun-
erpulsation), major bleeding requiring blood transfusion
fter acute reperfusion treatment, a history of leukopenia,
hrombocytopenia, or hepatic or renal dysfunction, evidence
or malignant diseases, or unwillingness to participate. The
thics review board of the Hospital of the Johann Wolfgang
oethe University of Frankfurt, Germany, approved the
rotocol, and the study was conducted in accordance with
he Declaration of Helsinki. Written, informed consent was
btained from each patient.
tudy design. The primary aim of the present pilot trial
as to assess the safety and feasibility of progenitor cell
herapy after MI with a one-year follow-up after therapy. In
ddition, as a secondary aim, various quantitative parame-
ers of myocardial and coronary vascular function were
ssessed in an exploratory fashion to generate hypotheses
nd to provide a rational basis for power calculation of
urther controlled trials. Quantitative parameters of the
xplorative analysis, invasively repeated in eligible patients
t four months, included LV angiography and intracoronary
oppler measurements, whereas echocardiography and
RI were also repeated after one year in subsets of patients.
Figure 1 illustrates the study design. As previously de-
cribed (14), patients were randomly assigned to receive
ntracoronary infusion of either BMC or CPC three toon; BMC  bone marrow-derived progenitor cells; CPC  circulating
agnetic resonance imaging; PCI  percutaneous coronary intervention.
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Intracoronary Progenitor Cells After AMI October 19, 2004:1690–9even days (median 4.9 days) after AMI. Two patients with
epeated AMI were excluded from further exploratory
nalysis. One patient refused follow-up angiography, but
nderwent clinical assessment. One patient received an
nsufficient number of cells owing to failure of preparation
f the syringe and, thus, was excluded from further explor-
tory analysis.
ransplantation protocol. In patients receiving BMC,
one marrow aspirates were obtained in the morning of the
ay of cell transplantation. In patients receiving CPC, 250
l of venous blood was collected immediately after random-
zation (24 h after the AMI), mononuclear cells were
urified and ex vivo cultured for three days, and then
e-infused into the infarct artery. After arterial puncture,
atients—pretreated with aspirin and clopidogrel—received
.500 to 10.000 U of heparin, and a bolus of abciximab
0.25 mg/kg) was given in the majority of patients prior to
ell therapy. Cells were infused via an over-the-wire balloon
atheter advanced into the stent previously implanted dur-
ng the acute reperfusion procedure and inflated with low
ressure to completely block blood flow for 3 min to allow
or adhesion and potential transmigration of the infused
ells through the endothelium. This maneuver was repeated
hree times to accommodate infusion of the total 10 ml
rogenitor cell suspension, interrupted by 3 min of reflow by
eflating the balloon to minimize extensive ischemia. After
ompletion of intracoronary cell transplantation, coronary
ngiography was repeated to ascertain vessel patency, ab-
ence of embolization, and unimpeded flow of contrast
aterial.
reparation and characterization of progenitor cells. As
reviously reported (14,15), after aspiration of 50 ml bone
arrow, BMC were isolated by Ficoll density gradient
entrifugation. After two washing steps, cells were re-
uspended in 10 ml X-vivo-10 medium (Biowhittaker,
pen, Germany). The cell suspension consists of heteroge-
eous cell populations including hematopoietic progenitor
ells, which were determined by fluorescence-activated cell
orter analysis using directly conjugated antibodies against
nti-human CD34 (FITC, Becton Dickinson, Heidelberg,
ermany), anti-CD45 (Becton Dickinson), and CD133
Miltenyi Biotech, Bergisch Gladbach, Germany), but also
ther cell types (e.g., side population cells, stromal cells, and
o on). Overall, a mean value of 5.5  3.9  106 CD34/
D45-positive cells was infused per patient. To assess
olony-forming units, BMC (1 105 per dish) were seeded
n methylcellulose plates (Methocult GF H4535 including
tem cell factor, granulocyte colony-stimulating factor,
ranulocyte-macrophage colony-stimulating factor,
nterleukin-3, interleukin-6; CellSystems, St. Katharinen,
ermany). Plates were studied under phase-contrast mi-
roscopy, and colony-forming units of granulocyte-
acrophage (colonies50 cells) were counted after 14 days of
ncubation by two independent investigators.
In patients receiving CPC, 250 ml of venous blood wasollected immediately after random assignment (24 h after ahe AMI). Mononuclear cells were suspended in X-vivo-15
edium (Biowhittaker) supplemented with 1 ng/ml carrier-
ree human recombinant vascular endothelial growth factor
R&D, Wiesbaden, Germany), 0.1 mol/l atorvastatin
Pfizer, Freiburg, Germany), and 20% human serum drawn
rom each individual patient. Cells were seeded at a density
f 6.4 105 cells/mm2 at fibronectin-coated dishes (Roche,
renzach, Germany). After three days of cultivation, cells
ere detached with 0.5 mmol/l ethylenediamine-tetraacetic
cid, washed twice, and re-suspended in a final volume of 10
l X-vivo-10 medium. The resulting cell suspension con-
ains a heterogeneous population of progenitor cells. How-
ver, more than 90% of the cells show endothelial charac-
eristics as demonstrated by Dil-acetylated low-density
ipoprotein-uptake and lectin binding and the expression of
ypical endothelial marker proteins including vascular endo-
helial growth factor-R2 (KDR) (ReliaTech, Braunschweig,
ermany), endoglin (CD105) (NeoMarkers, Asbach, Ger-
any), von Willebrand factor (Oncogene, Schwalbach,
ermany), and platelet endothelial cell adhesion molecule-1
PECAM-1/CD31) (Dianova, Hamburg, Germany)
14,16–18). For both cell types, the percentage of migrating
ells was determined as previously described (15).
arameters of safety and feasibility. Clinical, medication,
nd safety laboratory data were prospectively collected by
esearch nurses. Follow-up visits after two weeks, four
onths, and one year were performed by physicians. Pro-
edural complications were defined as any ventricular ar-
hythmia, thrombus formation, distal embolization, or in-
ury of the vessel associated with the progenitor cell infusion
atheterization procedure. In patients undergoing bone-
arrow puncture, potential bleeding complications were
ssessed. Laboratory safety parameters included C-reactive
rotein as a marker of inflammation and troponin T as a
arker of myocardial necrosis, both assessed prior to cell
herapy and after 24 h, and in a subset of patients at 14 days.
During hospitalization, any ventricular arrhythmias were
ocumented. Telemetry was routinely performed for 24 h
fter the procedure in all patients. In addition, the following
linical events were recorded: infarct vessel stent thrombo-
is, target vessel, and non-target vessel revascularization,
epeated MI (defined as creatine kinase elevation 2  upper
ormal limit), cerebral infarction, and death of any cause.
During 12 months’ clinical follow-up, the same parame-
ers were assessed. Causes for potential rehospitalization
uring follow-up were verified by review of the discharge
etters or charts of hospital stays. In addition, specific
ttention was paid to any potential signs or symptoms of
rrhythmia such as syncope during follow-up. In 47 pa-
ients, 24-h Holter monitoring was performed at 12
onths. At four months’ invasive follow-up coronary an-
iography, the degree of luminal narrowing at the target
esion stent intervention was documented by quantitative
ngiographic analysis (Medis, Leiden, the Netherlands). In
ddition, any newly diagnosed cancer was documented.
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October 19, 2004:1690–9 Intracoronary Progenitor Cells After AMIV angiography. The LV angiograms were obtained ac-
ording to standard acquisition guidelines immediately after
ercutaneous stent revascularization of the infarct artery and
t four months’ follow-up. The LV EF and volumes were
alculated with use of the area-length method (19), and
egional wall motion was determined with use of the
enterline chord method (20). After four months, left
entriculography was performed with identical projections
ccording to standard acquisition guidelines. In one patient
eceiving CPC, LV angiography was not suitable for anal-
sis, and one patient receiving BMC refused follow-up
ngiography, leaving 54 paired angiograms for exploratory
nalysis (Fig. 1).
RI. Cardiac MRI (1.5-T system, Magnetom Sonata,
iemens Medical Solutions, Erlangen, Germany) was per-
ormed in a total of 37 patients after MI as well as at four
onths and one year after progenitor cell therapy. All
mages were acquired using a phased-array body surface coil
ith 4 to 12 elements during breath-holds (max 12 s) and
ere electrocardiogram-triggered. Cine images with a slice
hickness of 8 mm were acquired throughout the entire left
entricle using contiguous two-dimensional True Fast Im-
ging in Steady state Precession sequences. The typical
n-plane resolution was 2.2  1.3 mm2. After intravenous
pplication of gadolinium-diethylenetriaminepentaacetate
Gd-DTPA) (0.2 mmol/kg body weight), “late enhance-
ent” imaging was performed with a delay time of 15 min.
ontiguous inversion recovery two-dimensional Turboflash
mages (Turbo Fast Low Angle Shot; True Fast Imaging in
teady state Precession) using an individually optimized
nversion time of 170 to 280 ms were acquired. Again, the
lice thickness was 8 mm, and the in-plane resolution varied
etween 1.7  1.4 mm2 and 1.4  1.4 mm2. Using the
RGUS software (Siemens, Erlangen, Germany), LV
unction (EF), end-systolic and end-diastolic volumes as
ell as LV mass normalized to body weight, and the
olumes of the regions revealing “late enhancement” were
alculated from both examinations.
tress echocardiography. At the day of cell transplanta-
ion, dobutamine stress echocardiography for the assess-
ent of viable myocardium was carried out in a subset of 44
atients before intracoronary cell infusion. Both resting and
obutamine stress echocardiography tests were performed
nd analyzed as previously described (21,22). Studies were
onducted with the patient in the left lateral position.
wo-dimensional echocardiography using a phased-array
lectronic ultrasound system (System V, Vingmed, Norway)
as performed in the four standard views: parasternal long-
nd short-views and apical four- and two-chamber views. A
2-lead electrocardiogram and blood pressure readings were
ecorded at baseline, at the end of each 3-min stage of
ncreasing doses of dobutamine, at peak stress, and every 3
in during recovery for at least 6 min or until all stress-
nduced wall motion abnormalities resolved. Contractile
eserve was defined as an improvement of regional wall wotion score index during low-dose dobutamine infusion
10 g/kg/min) in at least one segment.
tatistical analysis. Continuous variables are presented as
ean  SD and median. Categorical variables were com-
ared with either the chi-square test or the Fisher exact test.
tatistical comparisons between initial and follow-up data
ere performed in a non-parametric fashion using the
ilcoxon test. Non-parametric Mann-Whitney U or
ruskall-Wallis tests were used to compare continuous with
ategorical variables. Linear non-parametric correlation was
alculated using the Spearman correlation. Statistical signif-
cance was assumed if p  0.05. All statistical analysis was
erformed using SPSS (Version 11.5, SPSS Inc., Chicago,
llinois).
ESULTS
he demographic, clinical, and angiographic characteristics
f the study population as well as of the infused cells are
ummarized in Table 1. No significant differences existed in
ny of the baseline parameters.
rocedural safety. The procedure was well tolerated with
sually no or only mild angina during the 3 min of balloon
nflation for infusion of the cells in these patients shortly
fter MI. There were no procedural complications during
ardiac catheterization related to intracoronary progenitor
ell injections such as ventricular arrhythmias, new throm-
us formation, embolization after cell infusion, or dissection
ue to balloon inflations (Table 2). However, one patient
emonstrating a small residual thrombus at the proximal
tent edge experienced embolic occlusion of the very distal
essel after balloon dilation. Because the event occurred
efore cell infusion, it was not judged to be related to
rogenitor cell therapy itself. Nevertheless, because repeated
ntracoronary instrumentation required for intracoronary
ell infusion was most likely responsible for dislodgement of
he thrombus and subsequent distal vessel occlusion, this
omplication was judged as procedure-related. In this pa-
ient, troponin T increased from 6.2 ng/ml before cell
herapy to 7.3 ng/ml the next day, and creatine kinase
ncreased from 120 U/l to 136 U/l (reference 80 U/l). In
ll patients, Thrombolysis In Myocardial Infarction (TIMI)
lood flow did not worsen, and embolization after cell
nfusion could be ruled out at the final angiography. Overall,
here was no evidence for myocardial damage induced by
ell therapy: troponin T levels, obviously still elevated after
I, further declined 24 h after cell therapy (2.4 2.0 ng/ml
o 1.7 1.6 ng/ml; p  0.001) and normalized at 14 days
0.025  0.04 ng/ml) (Table 2). Likewise, there was no
vidence for a systemic proinflammatory response to cell
herapy, as overall C-reactive protein levels did not increase
fter cell therapy (3.1  2.4 mg/dl to 2.9  2.2 mg/dl; p 
.29) and further declined to 0.97  0.50 mg/dl at 14 days.
n addition, there were no bleeding complications associated
ith bone-marrow puncture in patients undergoing maxi-
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Intracoronary Progenitor Cells After AMI October 19, 2004:1690–9al anticoagulant and antiplatelet therapy for cardiac cath-
terization a few hours after the bone-marrow puncture.
n-hospital course. During 24-h telemetric monitoring,
o ventricular arrhythmias were detected (Table 3). One
atient (#19), who received CPC into the right coronary
rtery for inferior MI, and stent revascularization of a
oncomitant left anterior descending artery (LAD) stenosis
t the time of cell therapy, experienced an additional
nterior wall infarction due to stent thrombosis of the LAD
non-target vessel of prior cell infusion) three days after cell
Table 1. Baseline Characteristics
Risk factors
Age, yrs
Male gender
Hypertension
Hyperlipidemia
Diabetes
Smoking
Family history for CHD
CAD
1-vessel disease
2-vessel disease
Infarct treatment
Infarct-related vessel
LAD
LCX
RCA
PCI of second vessel
During infarct treatment procedure
During cell therapy procedure
Time to reperfusion/stent (median) (h)
TIMI flow post reperfusion (%)
Flow grade 2
Flow grade 3
Ejection fraction (visually estimated)
CPR during acute MI (n)
Creatine kinase max (U/l)*†
Creatine kinase-MB max (U/l)*
Cell therapy
Time stent to cell therapy (days)
Number of injected cells ( 106)
% Migrating cells
% CD34/CD45 (absolute cell number  10
% CD34/CD133 (absolute cell number  10
Colony-forming units/well
Discharge medication
Aspirin (%)
Clopidogrel (%)
ACE inhibitor (%)
Beta-blocker (%)
Statin (%)
Values are expressed as mean  SD. *Without CPR patien
vascular endothelial growth factor, §towards stromal cell-der
ACE  angiotensin-converting enzyme; BMC  bone m
coronary heart disease; CPC  circulating progenitor cell
descending; LCX  left circumflex; MI  myocardial infar
coronary artery; TIMI  Thrombolysis In Myocardial Infarherapy, which was successfully treated by immediate recan- ilization of the LAD. It was discovered afterwards that this
atient suffered from genetically determined severe anti-
hrombin III deficiency and, in addition, had a non–insulin-
ependent diabetes mellitus. Additionally patient (#25),
ith insulin-dependent diabetes mellitus, receiving BMC
nto the LAD after a large anterior infarction, experienced
dverse events including an MI and subsequent death: three
ays after cell therapy with concomitant stent revasculariza-
ion of a very proximal left circumflex stenosis, subacute
tent thrombosis of the LAD (target vessel of prior cell
CPC
(n  30)
BMC
(n  29)
p Valuen % n %
52 10 52 10 0.83
27 90 26 90 1.0
18 60 15 52 0.52
19 63 17 59 0.71
6 20 8 28 0.44
15 50 21 72 0.21
10 33 14 48 0.24
0.84
21 70 21 72
9 30 8 28
0.22
19 63 16 55
5 17 2 7
6 20 11 38
2 7 5 17 0.25
— 4
2 1
13 22 (4.5) 27  40 (14)
1.0
4 13 4 14
26 87 25 86
42 11 40  7.7 0.90
0 2 7 0.24
1,118  908 919  723 0.37
126 96 101 97 0.34
4.9  1.1 4.5  1.7 0.23
16  12 213 75 —
13 14‡ 5.5  5.0§ 0.10
1.1  0.9 —
(2.6  2.5)
0.12  0.10 —
(0.28  0.34)
123 86 —
30 100 28 100
30 100 28 100
29 97 28 100 1.0
30 100 28 100
30 100 28 100
per normal limit: 80 IU (men); 70 U/l (women). ‡Toward
actor-1.
progenitor cells; CAD  coronary artery disease; CHD 
 cardiopulmonary resuscitation; LAD  left anterior
PCI  percutaneous coronary intervention; RCA  right6)
6)
ts; †up
ived f
arrow
s; CPRnfusion) occurred, which was successfully revascularized.
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October 19, 2004:1690–9 Intracoronary Progenitor Cells After AMIowever, at day 5, additional stent thrombosis of the left
ircumflex artery occurred and the patient developed car-
iogenic shock, which subsequently led to death.
linical follow-up at 4 and 12 months. No further stent
hrombosis, MI, or death occurred beyond the initial
ospitalization period (Table 3). At one-year follow-up,
arget (infarct) vessel revascularization (excluding the one
n-hospital stent thrombosis) was performed in a total of 12
atients (21%), 7 (23%) in the CPC group, and 5 of 28
18%) patients discharged alive in the BMC group.
In addition, no syncope, ventricular arrhythmia, or cere-
ral infarction was observed. The 24-h Holter monitoring,
erformed in 47 patients at 12 months, revealed no evidence
Table 2. Procedural Safety of Intracoronary Pr
CP
(n 
Procedural complications* 0
CRP (mg/dl)
Before cell therapy 2.8  2.
24 h after cell therapy 2.6  2.
14 days after cell therapy (n  48) 0.65 0.
4 months follow-up 0.49  0.
Troponin
Before to cell therapy 2.3  1.
24 h after cell therapy 1.5  1.
14 days after cell therapy (n  46) 0.02 0.
Values are expressed as mean  SD (median). *Thrombosis
CRP  C-reactive protein; other abbreviations as in Tab
able 3. Clinical Events
CPC
(n  30)
BMC
(n  29)
n-hospital events
Death 0 1*
MI 1† 1*
Infarct vessel stent thrombosis 0 1*
Non-target vessel stent thrombosis 1† 1*
Cerebral infection 0 0
Ventricular arrhythmia (monitoring) 0 0
2-month follow-up (cumulative)
Death 0 1*
MI 1† 1*
Rehospitalization due to heart failure 0 0
Stent thrombosis after hospitalization 0 0
Infarct vessel revascularization‡ 7 6
Coronary bypass surgery 0 0
Cerebral infarction 0 0
Cancer 0 0
Syncope 0 0
Documented ventricular arrhythmia 0 0
Ventricular tachycardia in 24-h Holter
ECG (n  47)
0 0
umulative death or MI 1 1
umulative death, MI, or
rehospitalization due to heart failure
1 1
umulative death, MI, or infarct vessel
revascularization
8 6
Same patient, †same patient; ‡including revascularization due to in-hospital stent
hrombosis and to restenosis.
ECG  electrocardiogram; other abbreviations as in Table 1.
F
tf ventricular tachycardia. No case of cancer was detected
ntil 12 months’ follow-up.
Thus, there were no delayed adverse events related to
rogenitor cell therapy. None of the treated patients were
ehospitalized for treatment of heart failure. Thus, by
aplan-Meier analysis, survival free of death, recurrent MI,
r rehospitalization for heart failure was 97%. Figure 2
llustrates Kaplan-Meier curves for survival free of death,
ecurrent MI, and target (infarct) vessel revascularization.
uantitative LV angiography at four months. In the 54
atients suitable for exploratory analysis of LV function four
onths after transplantation of progenitor cells, the LV EF
ad significantly increased from 50  10% at baseline to
8.3  10% (p  0.001) (Table 4, Fig. 3). Detailed analysis
f regional wall motion revealed the most prominent im-
rovements in the border zone adjacent to the central infarct
rea (Table 4). The LV end-diastolic volume did not
ignificantly change, whereas LV end-systolic volume was
ignificantly reduced at four months’ follow-up in both
roups of patients.
Baseline LV EF (r  0.42, p  0.002) was the only
ignificant univariate predictor of improvement in EF dur-
ng the four months’ follow-up, whereas female gender (p
.07), maximal creatine kinase elevation (p  0.10), age
itor Cell Infusion
BMC
(n  29)
Both Cell
Groups
(n  54)
0 0
) 3.5  2.6 (2.6) 3.1  2.4 (2.3)
) 3.2  2.0 (2.8) 2.9  2.2 (2.3)
5) 1.1 1.3 (0.6) 0.82  0.97 (0.5)
3) 0.40 0.18 (0.3) 0.44 0.30 (0.3)
) 2.5  2.1 (1.9) 2.4  2.0 (1.85)
) 1.9  1.8 (1.5) 1.7  1.6 (1.4)
01) 0.03 0.04 (0.01) 0.03 0.04 (0.01)
lization, arrhythmia, or dissection related to cell infusion.ogen
C
30)
2 (2.0
3 (1.8
54 (0.
38 (0.
9 (1.7
4 (1.2
03 (0.igure 2. Event-free survival of death, recurrent myocardial infarction, or
arget vessel revascularization (Kaplan-Meier analysis).
a
h
d
0
f
o
i
p
d
L
0
t
i
c
r
p
r
L
c
A
m
c
(
L
p

f
g
fi
m
y
t
a
6
v
(
t
m
w
n
m
D
T
i
s
i
c
f
A
S
B
w
r
p
c
s
d
b
c
s
s
r
u
l
r
T
E
E
E
R
I
V th cell
1696 Schächinger et al. JACC Vol. 44, No. 8, 2004
Intracoronary Progenitor Cells After AMI October 19, 2004:1690–9bove the median of 53 years (p  0.49), presence of
ypertension (p  0.32), hypercholesterolemia (p  0.88),
iabetes (p  0.87), extent of coronary artery disease (p 
.51), time to revascularization therapy (p  0.26), time
rom revascularization to progenitor cell therapy (p 0.44),
r occurrence of a restenosis (p  0.91) did not predict
mprovement of LV EF. Figure 4 illustrates that those
atients with the most severe impairment in LV function
emonstrated the largest absolute improvements in global
V EF irrespective of the cell type infused (r  0.42; p 
.002). This correlation remains statistically significant, if
he two outliers with the lowest initial EF and the best
mprovement of EF are excluded (r  0.34; p  0.014).
Finally, to investigate whether contractile improvement is
onfined to patients exhibiting the presence of contractile
eserve prior to progenitor cell therapy, we determined any
otential association between low-dose dobutamine-
ecruitable contractile reserve and improvement in global
V EF in a subset of 44 patients undergoing stress echo-
ardiography before intracoronary progenitor cell infusion.
s illustrated in Figure 5, improvements in LV EF at four
onths did not differ between patients with (n  35)
ompared to those without evidence for contractile reserve
n  9) before cell therapy.
V function by MRI at 12 months. In a subset of 37
atients, contrast-enhanced MRI was serially performed 10
5.9 days after AMI, at 4 months’ and at 12 months’
ollow-up. As illustrated in Figure 6, MRI-determined
lobal LV EF not only significantly improved within the
rst 4 months, but further increased between month 4 and
onth 12 resulting in a total increase of 9.3  8.0% one
ear after progenitor cell treatment (Fig. 6A). At the same
ime, late enhancement volume as a measure of infarct size
lso significantly decreased from month 4 to month 12 (Fig.
able 4. Left Ventricular Angiography: Quantitative Global and
CPC
(n  27)
Cell Therapy 4 Months Cell
jection fraction (%) 51  10 (50) 59  10 (62) 49
nd-diastolic volume (ml) 107  26 (102) 109  33 (106) 111
nd-systolic volume (ml) 52  16 (53) 42  18 (40) 56
egional wall motion
(SD/chord)
Infarct 1.5  0.28
(1.43)
0.69  0.61
(0.62)
1.52
(
Infarct center 1.59  0.38
(1.50)
0.85  0.71
(0.96)
1.71
(
Infarct border 1.44  0.20
(1.43)
0.54  0.60
(0.61)
1.41
(
nfarct extension
(hypokinetic chords)
38  14 (39) 20  16 (14) 40
alues are expressed as mean  SD (median). *Cell therapy versus 4 months for bo
Abbreviations as in Table 1.B) resulting in an overall reduction of late enhancement molume by 34  34%. The MRI-determined LV mass
adjusted for body surface) decreased from 86  15 ml/m2
o 79  15 ml/m2 at 4 months and remained at 77  15
l/m2 at 12 months. Thus, improved global LV function
as observed despite the lack of reactive hypertrophy of
on-infarcted myocardium, suggesting a favorable LV re-
odeling process following AMI.
ISCUSSION
he final results of the TOPCARE-AMI trial indicate that
ntracoronary infusion of CPC or BMC: 1) is feasible and
afe in patients with AMI, 2) is associated with significant
mprovements in global LV function, and 3) show signifi-
ant reductions in LV end-systolic volumes, suggesting a
avorable LV remodeling process over one year following
MI.
afety and feasibility. Progenitor cell therapy with either
MC or CPC after a median of 4.9 days following an MI
as in general well tolerated without any complications
elated to the cell-infusion procedure itself. However, one
atient suffered from a procedure-related thrombotic distal
oronary vessel occlusion prior to intracoronary cell infu-
ion. Importantly, there was no evidence for myocardial
amage or aggravation of inflammatory responses incurred
y intracoronary progenitor cell infusion. Although we
annot exclude the possibility that intracoronary cell infu-
ion may have contributed to the two re-infarctions ob-
erved in the present study, the incidence of death and/or
e-infarction (3.4%) compares favorably with recent trials
sing stent percutaneous coronary intervention for revascu-
arization of AMI (3,4,23).
Moreover, target vessel revascularization rate due to
estenosis (21%) was within the range expected from bare
onal Left Ventricular Function
BMC
(n  27)
Both Cell Groups
(n  54)
p Value*apy 4 Months Cell Therapy 4 Months
(50) 57  10 (59) 50  10 (50) 58  10 (60) 0.001
(111) 102  31 (99) 109  27 (107) 105  31 (101) 0.45
(53) 45  21 (42) 54  19 (53) 44  20 (41) 0.001
6 0.60  0.65
(0.48)
1.51  0.26
(1.45)
0.64  0.63
(0.60)
0.001
4 0.81  0.66
(0.65)
1.65  0.36
(1.58)
0.83  0.68
(0.86)
0.001
9 0.44  0.67
(0.48)
1.42  0.19
(1.41)
0.49  0.63
(0.55)
0.001
(40) 21  18 (21) 39  15 (39) 21  17 (18) 0.001
groups.Regi
Ther
 10
 29
 21
 0.2
1.53)
 0.3
1.60)
 0.1
1.35)
 15etal stents used in patients with AMI (24). Thus, repeated
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lanted stent still not covered by endothelium—required to
nfuse the progenitor cells—a couple of days after AMI did
ot adversely affect four-month angiographic restenosis
ates nor late (one year) target vessel revascularization rates.
Thus, the present data argue against recent speculations
hat progenitor cell therapy—combined with granulocyte
olony-stimulating factor-induced mobilization—might en-
ance the restenosis process (MAGIC trial [25]). The 10
atients reported in the MAGIC trial were a heterogeneous
opulation with previous MI varying from 2 to 270 days.
ost importantly, granulocyte colony-stimulating factor
reatment was initiated before percutaneous coronary inter-
ention of the infarct-related stenosis, which might—by
tudy design— enhance plaque inflammation, a well-
stablished predictor of restenosis (26).
igure 3. Left ventricular ejection fraction, measured by quantitative left
entricular angiography initially and at four-month follow-up for patients
eceiving circulating progenitor cells (CPC) or bone marrow-derived
rogenitor cells (BMC). Bars represent mean  SD.Finally, in the TOPCARE-AMI trial, neither during the
d
mnitial hospital stay nor during the 12-month follow-up
eriod was there any evidence of malignant ventricular
rrhythmias. In contrast, life-threatening ventricular ar-
hythmias have been reported following intramyocardial
njection of skeletal myoblasts (27) in patients with chronic
schemic cardiomyopathy. Although patients with chronic
schemic cardiomyopathy are different from patients of the
resent study, one might speculate that intracoronary infu-
ion of progenitor cells may favor homing of the cells into
yocardial areas with preserved nutrient blood flow in
ontrast to injecting cells into scar tissue. Moreover, CPC,
hich ex vivo transdifferentiate into cardiomyocytes, were
igure 4. Correlation between initial global left ventricular ejection frac-
ion and improvement of ejection fraction (difference between absolute
alues) during four-month follow-up (both assessed by quantitative left
entricular angiography). BMC  bone marrow-derived progenitor cells;
PC  circulating progenitor cells.
igure 5. Improvement of global left ventricular ejection fraction after four
onths assessed by quantitative left ventricular angiography according to
he presence or absence of contractile reserve by low-dose stress echocar-
iography before intracoronary progenitor cell infusion. AMI  acute
yocardial infarction.
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ally integrate (28), in contrast to skeletal myoblasts (29).
V function after progenitor cell therapy. The LV EF
ncreased by an absolute 8.7  8.3% four months following
ntracoronary progenitor cell infusion. However, we cannot
xclude that ischemic preconditioning due to repeated
alloon occlusions of the infarct artery required for intra-
oronary progenitor cell application 3 to 7 days after AMI
ay have contributed to the observed increase in global LV
unction.
Analysis of LV function by MRI one year after progen-
tor cell infusion not only documented a sustained improve-
ent in global EF, but revealed the lack of infarct expansion
s evidenced by reduced end-systolic volumes and un-
hanged end-diastolic volumes as well as absent reactive
ypertrophy of non-infarcted segments as evidenced by a
reserved significant reduction of LV mass between month
and month 12 compared to the acute phase post-MI.
ormally, both end-diastolic and end-systolic LV volumes
ignificantly increase by 20% over one year post-MI (30),
process termed “LV remodeling.” Thus, transplantation of
rogenitor cells early after an AMI was associated with a
avorable LV remodeling process over a one-year follow-up
eriod.
Experimental studies suggested that improved ventricular
unction by progenitor cell transplantation following an MI
igure 6. Magnetic resonance imaging (MRI)-determined improvement
n global left ventricular ejection fraction (A) and reduction in late
nhancement volume (B) after 4 and 12 months.s mainly due to stimulated neovascularization preventing Eate myocardial remodeling through enhanced blood flow,
escue of hibernating myocardium, reduction of myocardial
brosis, and decreased apoptosis of hypertrophied myocytes
n the peri-infarct region (6,7,31,32). In addition, intramyo-
ardial injection of BMC was shown to lead to regeneration
f significant amounts of contracting myocardium (5,33),
lthough the capacity of purified hematopoietic progenitor
ells to differentiate into cardiac myocytes has been ques-
ioned recently (34,35). Obviously, the present clinical study
annot disclose the cellular mechanisms associated with the
bserved improved LV contractility and remodeling pro-
esses. However, improvement in global LV EF was inde-
endent of the presence of contractile reserve, indicating
hat rescue of hibernating myocardium may not fully ac-
ount for the observed beneficial effects. Moreover, im-
rovement in LV function associated with a further reduc-
ion in MRI-determined infarct size observed between
onth 4 and month 12 suggests that intracoronary progen-
tor cell infusion may interfere with the endogenous infarct
ealing process. It is conceivable that homing of progenitor
ells may modify post-infarction LV remodeling via the
elease of various growth factors attracting both circulating
nd tissue resident cardiac progenitor cells, thereby enhanc-
ng endogenous repair mechanisms of the myocardium
36,37).
In summary, results of the present study document that
ntracoronary infusion of either BMC or CPC is safe and
easible in patients after AMI successfully revascularized by
tent implantation. Although the precise mechanisms of
unctional improvement remain to be elucidated, the excel-
ent safety profile, combined with a favorable LV remodel-
ng process following an MI provides the rationale for larger
andomized, double-blind trials, like the ongoing Reinfu-
ion of Enriched Progenitor Cells And Infarct Remodeling
n Acute Myocardial Infarction (REPAIR-AMI) multi-
enter trial, which will differentiate a potential progenitor
ell associated effect from the effects of ischemic precondi-
ioning due to repeated balloon occlusion of the infarct
rtery required for intracoronary progenitor cell application
hree to seven days after an AMI. Ultimately, based on the
bservations of the present trial, this novel form of regen-
ration enhancement therapy holds the promise to interfere
ith the development of post-infarction heart failure.
cknowledgments
e gratefully acknowledge the enthusiastic support by the
taff of our catheterization laboratories, by research nurses
. Mantz, H. Braun, and I. Geweyer, and by technicians T.
asper (cell processing) and A. Koch (MRI).
eprint requests and correspondence: Dr. Andreas M. Zeiher,
epartment of Internal Medicine IV, Johann Wolfgang Goethe-
niversity, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany.
-mail: zeiher@em.uni-frankfurt.de.
R1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
1699JACC Vol. 44, No. 8, 2004 Schächinger et al.
October 19, 2004:1690–9 Intracoronary Progenitor Cells After AMIEFERENCES
1. Krum H, Gilbert RE. Demographics and concomitant disorders in
heart failure. Lancet 2003;362:147–58.
2. Lange RA, Hillis LD. Reperfusion therapy in acute myocardial
infarction. N Engl J Med 2002;346:954–5.
3. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty
with stenting, with or without abciximab, in acute myocardial infarc-
tion. N Engl J Med 2002;346:957–66.
4. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein
IIb/IIIa inhibition with coronary stenting for acute myocardial infarc-
tion. N Engl J Med 2001;344:1895–903.
5. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate
infarcted myocardium. Nature 2001;410:701–5.
6. Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of
ex vivo expanded endothelial progenitor cells for myocardial ischemia.
Circulation 2001;103:634–7.
7. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of
ischemic myocardium by human bone-marrow-derived angioblasts
prevents cardiomyocyte apoptosis, reduces remodeling and improves
cardiac function. Nat Med 2001;7:430–6.
8. Fuchs S, Baffour R, Zhou YF, et al. Transendocardial delivery of
autologous bone marrow enhances collateral perfusion and regional
function in pigs with chronic experimental myocardial ischemia. J Am
Coll Cardiol 2001;37:1726–32.
9. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells
repair the infarcted heart, improving function and survival. Proc Natl
Acad Sci U S A 2001;98:10344–9.
0. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium
by autologous intracoronary mononuclear bone marrow cell transplan-
tation in humans. Circulation 2002;106:1913–8.
1. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis
in ischaemic myocardium by intramyocardial autologous bone marrow
mononuclear cell implantation. Lancet 2003;361:47–9.
2. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial,
autologous bone marrow cell transplantation for severe, chronic isch-
emic heart failure. Circulation 2003;107:2294–302.
3. Stamm C, Westphal B, Kleine HD, et al. Autologous bone-marrow
stem-cell transplantation for myocardial regeneration. Lancet 2003;
361:45–6.
4. Assmus B, Schachinger V, Teupe C, et al. Transplantation Of
Progenitor Cells And Regeneration Enhancement in Acute Myocar-
dial Infarction (TOPCARE-AMI). Circulation 2002;106:3009–17.
5. Britten MB, Abolmaali N, Assmus B, et al. Infarct remodeling after
intracoronary progenitor cell treatment in patients with acute myocar-
dial infarction (TOPCARE-AMI): mechanistic insights from serial
contrast-enhanced magnetic resonance imaging. Circulation 2003;108:
2212–8.
6. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhib-
itors (statins) increase endothelial progenitor cells via the PI 3-kinase/
Akt pathway. J Clin Invest 2001;108:391–7.
7. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating
endothelial progenitor cells by statin therapy in patients with stable
coronary artery disease. Circulation 2001;103:2885–90.
8. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory
activity of circulating endothelial progenitor cells inversely correlate
with risk factors for coronary artery disease. Circ Res 2001;89:E1–7.
9. Dodge HT, Sandler H, Ballew DW, et al. The use of biplane
angiography for the measurement of left ventricular volume in man.
Eur Heart J 1960;60:762–76.0. Sheehan FH, Bolson EL, Dodge HT, Mathey DG, Schofer J,
Woo HW. Advantages and applications of the centerline method forcharacterizing regional ventricular function. Circulation 1986;
74:293–305.
1. Schiller NB, Shah PM, Crawford M, et al. Recommendations for
quantitation of the left ventricle by two-dimensional echocardiogra-
phy. American Society of Echocardiography Committee on Standards,
Subcommittee on Quantitation of Two-Dimensional Echocardio-
grams. J Am Soc Echocardiogr 1989;2:358–67.
2. Pierard LA, De Landsheere CM, Berthe C, Rigo P, Kulbertus HE.
Identification of viable myocardium by echocardiography during do-
butamine infusion in patients with myocardial infarction after throm-
bolytic therapy: comparison with positron emission tomography. J Am
Coll Cardiol 1990;15:1021–31.
3. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of
coronary angioplasty with fibrinolytic therapy in acute myocardial
infarction. N Engl J Med 2003;349:733–42.
4. Neumann F-J, Kastrati A, Schmitt C, et al. Effect of glycoprotein
IIb/IIIa receptor blockade with abciximab on clinical and angiographic
restenosis rate after the placement of coronary setnts following acute
myocardial infarction. J Am Coll Cardiol 2000;35:915–21.
5. Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion
of peripheral blood stem-cells mobilised with granulocyte-colony
stimulating factor on left ventricular systolic function and restenosis
after coronary stenting in myocardial infarction: the MAGIC cell
randomised clinical trial. Lancet 2004;363:751–6.
6. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB.
In-stent restenosis: contributions of inflammatory responses and arte-
rial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224–
30.
7. Smits PC, van Geuns RJ, Poldermans D, et al. Catheter-based
intramyocardial injection of autologous skeletal myoblasts as a primary
treatment of ischemic heart failure: clinical experience with six-month
follow-up. J Am Coll Cardiol 2003;42:2063–9.
8. Badorff C, Brandes RP, Popp R, et al. Transdifferentiation of
blood-derived human adult endothelial progenitor cells into function-
ally active cardiomyocytes. Circulation 2003;107:1024–32.
9. Hagege AA, Carrion C, Menasche P, et al. Viability and differentia-
tion of autologous skeletal myoblast grafts in ischaemic cardiomyop-
athy. Lancet 2003;361:491–2.
0. Schroeder AP, Houlind K, Pedersen EM, Nielsen TT, Egeblad H.
Serial magnetic resonance imaging of global and regional left ventric-
ular remodeling during 1 year after acute myocardial infarction.
Cardiology 2001;96:106–14.
1. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-
induced mobilization of bone marrow-derived endothelial progenitor
cells for neovascularization. Nat Med 1999;5:434–8.
2. Murohara T, Ikeda H, Duan J, et al. Transplanted cord blood-derived
endothelial precursor cells augment postnatal neovascularization.
J Clin Invest 2000;105:1527–36.
3. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells
modified with Akt prevent remodeling and restore performance of
infarcted hearts. Nat Med 2003;9:1195–201.
4. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL,
Robbins RC. Haematopoietic stem cells adopt mature haematopoietic
fates in ischaemic myocardium. Nature 2004;428:668–73.
5. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem
cells do not transdifferentiate into cardiac myocytes in myocardial
infarcts. Nature 2004;428:664–8.
6. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are
multipotent and support myocardial regeneration. Cell 2003;114:763–76.
7. Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from
adult myocardium: homing, differentiation, and fusion after infarction.
Proc Natl Acad Sci U S A 2003;100:12313–8.
